Showing 7401-7410 of 9758 results for "".
- African-American Organ Transplant Recipients at Risk for Skin Cancerhttps://practicaldermatology.com/news/african-american-organ-transplant-recipients-at-risk-for-skin-cancer/2458428/All organ transplant recipients, regardless of race, should receive routine, total-body screenings for skin cancer, according to researchers from Drexel University College of Medicine in Philadelphia. Out of 259 nonwhite transplant recipients who were evaluated in the study, 19 skin
- Allergan Bolsters Medical Derm Portfolio with Vitae Acquisitionhttps://practicaldermatology.com/news/allergan-to-acquire-vitae-pharmaceuticals/2458435/Allergan plc is acquiring Vitae Pharmaceuticals, Inc., a clinical-stage biotechnology company. The move will serve to bolster Allergan’s medical dermatology pipeline, with the addition of VTP-43742, a Phase 2 first-in-class, orally active ROR?t (retin
- Santalis Pharmaceuticals Starts Phase 2 Study of New Sandalwood Oil-based AD Therapyhttps://practicaldermatology.com/news/australias-santalis-pharmaceuticals-starts-phase-2-study-of-new-ad-therapy/2458445/Santalis Pharmaceuticals has enrolled the first patient in a Phase 2 Study of 5% East Indian Sandalwood Oil (EISO) cream for the treatment of atopic dermatitis (AD). Up to 60 patients aged 3 months to 65 with a clinically stable diagnosis of AD who have a total body surface
- Hair Transplants Make Men Look Younger, Hotterhttps://practicaldermatology.com/news/hair-transplants-make-men-look-younger-hotter/2458450/Once-balding men who undergo hair transplants are seen as more youthful, attractive, successful and approachable, new research suggests. In 2014, hair transplant was among the most common cosmetic services sought by men, with more than 11, 000 procedures performed, according to info
- It's So Far, So Good for BioPharmX's New Acne Drughttps://practicaldermatology.com/news/its-so-far-so-good-for-biopharmxs-new-acne-drug/2458458/BioPharmX Corporation’s novel topical minocycline, BPX-01, reduced facial P. acnes by more than 90 percent after four weeks, new research shows. In the Phase 2a study, a daily 10 mg dose of topical minocycline offered P. acnes r
- Face-Aging App May Encourage Sun-Safe Behaviorhttps://practicaldermatology.com/news/face-aging-app-may-encourage-sun-safe-behavior/2458460/Appealing to their vanity may be the best way to encourage young women to practice sun-safe behaviors, a new study shows. The new research, published in
- Billionaire John Paul DeJoria Bets Big on Aubío for Cold Sores and Maybe Morehttps://practicaldermatology.com/news/billionaire-john-paul-digorio-bets-on-aubo-for-cold-sores-and-maybe-more/2458461/Billionaire John Paul DiJoria of Paul Mitchell Professional Hair Care Products and Patron Tequila fame is putting his money where his mouth is --- literally. DeJoria is now investing “heavily” in a new natural and sustainably produced over-the-counter (OTC) col
- Paratek Initiates Phase 3 Study of Oral Omadacycline for MRSA, Acute Skin Infectionshttps://practicaldermatology.com/news/paratek-initiates-phase-3-study-of-oral-omadacycline-for-mrsa-acute-skin-infections/2458465/The first patient has been dosed in Paratek Pharmaceuticals, Inc.’s second pivotal Phase 3 study of omadacycline for acute bacterial skin and skin structure infections (ABSSSI). Omadacycline is a new once-daily oral and IV, well-tolerated
- Skin Cancer Foundation Calls for Grant Proposals for the 2017 Research Grant Awards Programhttps://practicaldermatology.com/news/skin-cancer-foundation-calls-for-grant-proposals-for-the-2017-research-grant-awards-program/2458466/The Skin Cancer Foundation is calling for grant proposals for their 2017 Research Grant Awards Program. Four grants of $25,000 will be awarded to research projects and clinical studies related t
- BEVL Blasts Off: New Mobile Network Seeks to Connect Aesthetic Proshttps://practicaldermatology.com/news/bevl-blasts-off-new-mobile-network-seeks-to-connect-aesthetic-pros/2458474/Meet BEVL, a new mobile network that connects medical aesthetics professionals. In private beta testing since June, BEVL is now accessible via iOS, Android and th